Introduction: When quality cytology screening is implemented in health networks, there is a ? reduction in the incidence of cervical cancer. However, due to the socio-economic differences between regions in Brazil, even though there is a satisfactory supply of screening for the disease, a proportion of avoidable deaths from cervical cancer still persists. Objectives: Describe the scenario of the pathology in question through the correlation between its screening and the level of lethality. Methods: This is an ecological and descriptive time series study, which analyzed the relationship between malignant cervical cancer and its mortality rate by federative unit of notification, in the period from 2020 to 2024. The study used secondary data from public and recognized sources, integrating epidemiological information and SUS hospital mortality records. Results: Between 2020 and 2024, 32,768.745 cervical cytology tests were carried out, of which 32,085.288 were screened and around 26,918.387 had some abnormality in the result. Race/color was self-declared by a large proportion of the women (13,393.724), and the age group between 40 and 44 was the one with the largest number of tests (4,028.840). The most frequent histopathological findings were low-grade lesions (CIN 1) or lesions due to HPV infection (229,510), with the state of Minas Gerais having the highest number of cases of this nature (31,549), while the least frequent was invasive squamous cell carcinoma (11,245), with the state of Pará registering the highest number of cases (569). Conclusion: The study showed the importance of cytological screening in the early detection of cervical cancer, with a predominance of low-grade lesions among the findings. The persistence of advanced cases, such as invasive squamous cell carcinoma, especially in some regions, points to inequalities in access to diagnosis and timely treatment. The findings reinforce the importance of the continuity and qualification of public prevention policies, with a special focus on the most vulnerable populations and in states with a higher incidence of serious lesions.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
